170 related articles for article (PubMed ID: 34253417)
1. Effectiveness of 13-valent pneumococcal conjugate vaccine against community acquired pneumonia among children in China, an observational cohort study.
Zhang T; Zhang J; Shao X; Feng S; Xu X; Zheng B; Liu C; Dai Z; Jiang Q; Gessner BD; Chen Q; Zhu J; Luan L; Tian J; Zhao G
Vaccine; 2021 Jul; 39(33):4620-4627. PubMed ID: 34253417
[TBL] [Abstract][Full Text] [Related]
2. Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017 - April 2019.
Liapikou A; Konstantinidis A; Kossyvaki V; Skiadas J; Menegas D; Méndez C; Beavon R; Begier E; Gessner BD; Milionis H; Tsimihodimos V; Baxevanos G; Argiriadou T; Terrovitou C; Toumbis M;
Hum Vaccin Immunother; 2022 Nov; 18(5):2079923. PubMed ID: 35703733
[TBL] [Abstract][Full Text] [Related]
3. A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands.
Gessner BD; Jiang Q; Van Werkhoven CH; Sings HL; Webber C; Scott D; Gruber WC; Grobbee DE; Bonten MJM; Jodar L
Vaccine; 2019 Jul; 37(30):4147-4154. PubMed ID: 31155413
[TBL] [Abstract][Full Text] [Related]
4. The Evolution and Distribution of Pneumococcal Serotypes in Adults Hospitalized With Community-Acquired Pneumonia in Spain Using a Serotype-Specific Urinary Antigen Detection Test: The CAPA Study, 2011-2018.
Torres A; Menéndez R; España PP; Fernández-Villar JA; Marimón JM; Cilloniz C; Méndez R; Egurrola M; Botana-Rial M; Ercibengoa M; Méndez C; Cifuentes I; Gessner BD;
Clin Infect Dis; 2021 Sep; 73(6):1075-1085. PubMed ID: 33851220
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of 13-valent pneumococcal conjugate vaccine on all-cause pneumonia in children under 5 years in Shanghai, China: An observational study.
Tian J; Zheng B; Yang L; Guan Y; Xu C; Wang W
Vaccine; 2023 Sep; 41(41):5979-5986. PubMed ID: 37620204
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in Japan.
Nakashima K; Suzuki K; Aoshima M; Murabata M; Kondo K; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
Vaccine; 2022 Nov; 40(46):6589-6598. PubMed ID: 36184405
[TBL] [Abstract][Full Text] [Related]
7. Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).
Webber C; Patton M; Patterson S; Schmoele-Thoma B; Huijts SM; Bonten MJ;
Vaccine; 2017 Mar; 35(9):1266-1272. PubMed ID: 28173960
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of community-acquired pneumonia in the era of extended serotype-covering multivalent pneumococcal conjugate vaccines.
Heo JY; Seo YB; Jeong HW; Choi MJ; Min KH; Choi WS; Lee J; Noh JY; Cheong HJ; Kim WJ; Song JY
Vaccine; 2020 Nov; 38(49):7747-7755. PubMed ID: 33164798
[TBL] [Abstract][Full Text] [Related]
9. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children.
Angoulvant F; Levy C; Grimprel E; Varon E; Lorrot M; Biscardi S; Minodier P; Dommergues MA; Hees L; Gillet Y; Craiu I; Zenkhri F; Dubos F; Guen CG; Launay E; Martinot A; Cohen R
Clin Infect Dis; 2014 Apr; 58(7):918-24. PubMed ID: 24532543
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of the 13-valent pneumococcal conjugate vaccine against adult pneumonia in Italy: a case-control study in a 2-year prospective cohort.
Prato R; Fortunato F; Cappelli MG; Chironna M; Martinelli D
BMJ Open; 2018 Mar; 8(3):e019034. PubMed ID: 29581200
[TBL] [Abstract][Full Text] [Related]
11. A population-based analysis to determine the impact of the 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in British Columbia, Canada.
Vadlamudi NK; Patrick DM; Rose C; Sadatsafavi M; Hoang L; Marra F
Vaccine; 2022 Feb; 40(7):1047-1053. PubMed ID: 35012778
[TBL] [Abstract][Full Text] [Related]
12. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults.
Suaya JA; Jiang Q; Scott DA; Gruber WC; Webber C; Schmoele-Thoma B; Hall-Murray CK; Jodar L; Isturiz RE
Vaccine; 2018 Mar; 36(11):1477-1483. PubMed ID: 29429807
[TBL] [Abstract][Full Text] [Related]
13. Pneumococcal Conjugated Vaccine Reduces the High Mortality for Community-Acquired Pneumonia in the Elderly: an Italian Regional Experience.
Baldo V; Cocchio S; Gallo T; Furlan P; Romor P; Bertoncello C; Buja A; Baldovin T
PLoS One; 2016; 11(11):e0166637. PubMed ID: 27846277
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Pneumococcal Vaccination Against Pneumococcal Pneumonia Hospitalization in Older Adults: A Prospective, Test-Negative Study.
Heo JY; Seo YB; Choi WS; Kim EJ; Jeong HW; Lee J; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Song JY
J Infect Dis; 2022 Mar; 225(5):836-845. PubMed ID: 34537847
[TBL] [Abstract][Full Text] [Related]
15. Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years.
Greenberg D; Givon-Lavi N; Ben-Shimol S; Ziv JB; Dagan R
Vaccine; 2015 Aug; 33(36):4623-9. PubMed ID: 26116251
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of 13-valent pneumococcal conjugate vaccine on radiological primary end-point pneumonia among cases of severe community acquired pneumonia in children: A prospective multi-site hospital-based test-negative study in Northern India.
Awasthi S; Kohli N; Agarwal M; Pandey CM; Rastogi T; Pandey AK; Roy C; Mishra K; Verma N; Kumar CB; Jain PK; Yadav R; Dhasmana P; Chauhan A; Mohindra N; Shukla RC
PLoS One; 2022; 17(12):e0276911. PubMed ID: 36520841
[TBL] [Abstract][Full Text] [Related]
17. Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis.
McLaughlin JM; Jiang Q; Gessner BD; Swerdlow DL; Sings HL; Isturiz RE; Jodar L
Vaccine; 2019 Oct; 37(43):6310-6316. PubMed ID: 31522807
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology of hospitalised paediatric community-acquired pneumonia and bacterial pneumonia following the introduction of 13-valent pneumococcal conjugate vaccine in the national immunisation programme in Japan.
Takeuchi N; Naito S; Ohkusu M; Abe K; Shizuno K; Takahashi Y; Omata Y; Nakazawa T; Takeshita K; Hishiki H; Hoshino T; Sato Y; Ishiwada N
Epidemiol Infect; 2020 Apr; 148():e91. PubMed ID: 32299523
[TBL] [Abstract][Full Text] [Related]
19. Long-term Association of 13-Valent Pneumococcal Conjugate Vaccine Implementation With Rates of Community-Acquired Pneumonia in Children.
Ouldali N; Levy C; Minodier P; Morin L; Biscardi S; Aurel M; Dubos F; Dommergues MA; Mezgueldi E; Levieux K; Madhi F; Hees L; Craiu I; Gras Le Guen C; Launay E; Zenkhri F; Lorrot M; Gillet Y; Béchet S; Hau I; Martinot A; Varon E; Angoulvant F; Cohen R
JAMA Pediatr; 2019 Apr; 173(4):362-370. PubMed ID: 30715140
[TBL] [Abstract][Full Text] [Related]
20. Rethinking number-needed-to-vaccinate for pneumococcal conjugate vaccines in older adults: Current and future implications.
McLaughlin JM; Swerdlow DL; Isturiz RE; Jodar L
Vaccine; 2017 Sep; 35(40):5360-5365. PubMed ID: 28863866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
